![Namir Hassan](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Provenance du réseau au premier degré de Namir Hassan
Entité | Type d'entité | Industrie | |
---|---|---|---|
Zelluna Immunotherapy AS
![]() Zelluna Immunotherapy AS BiotechnologyHealth Technology Zelluna Immunotherapy AS engages in research and development on biotechnology. The company is headquartered in Oslo, Norway.
6
| Holding Company | Biotechnology | 6 |
Graphique Sociétés connectées au second degré
Relation dans plusieurs entreprises
Sociétés connectées à Namir Hassan via son réseau personnel
Société | Secteur | Personnes liées | Poste principal |
---|---|---|---|
Accession Therapeutics Limited
![]() Accession Therapeutics Limited BiotechnologyHealth Technology Accession Therapeutics Limited is a British biotech company that is developing novel immuno-oncology therapeutics to eradicate cancers by harnessing the immune system more powerfully than ever before. The company is based in Oxford, UK and was founded in 2020 by Bent K. Jakobsen, who has been the CEO since then. The company's product, Trocept, is the first approach that meets the three requirements of being highly specific, broad in action to kill all cancer cell variants present, and potent in activating the full immune system arsenal local to the tumour. The team is built around successful biotech entrepreneurs experienced in taking projects through to the clinic and is supported by a Board comprising experienced international healthcare investors. | Biotechnology | Founder Director/Board Member | |
Nextera AS
![]() Nextera AS Miscellaneous Commercial ServicesCommercial Services Nextera AS provides drug research for therapeutic interventions for autoimmune diseases, chronic infections, and cancer. It offers platform for protein engineering and evolution, such as life sciences, drug discovery, and lead optimization fields. The firm’s core competence lies within protein engineering and evolution utilizing its technology to epitope discovery and epitope validation, as well as lead-candidate generation and validation in-vitro. The company was founded by Geir Åge Løset and Inger Sandlie in 2009 and is headquartered in Oslo, Norway. | Miscellaneous Commercial Services | Chairman Director/Board Member | |
APIM Therapeutics AS
![]() APIM Therapeutics AS Pharmaceuticals: MajorHealth Technology APIM Therapeutics AS develops and commercializes novel anti-cancer therapies. It offers a physiological intervention point allowing the potentiation of the action of clinical drugs across multiple cancer indications. The company focuses on the development and commercialization of novel anti-cancer therapies potentiating chemo-therapy induced responses in cancer cells. The company was founded by Marit Otterlei in 2009 and is headquartered in Trondheim, Norway. | Pharmaceuticals: Major | Director/Board Member | |
BI Norwegian Business School | College/University | Graduate Degree | |
Nucligen AS | Director/Board Member | ||
Radforsk | Chief Investment Officer | ||
PHOTOCURE ASA | Medical Specialties | Director/Board Member | |
Ernst & Young AS
![]() Ernst & Young AS Miscellaneous Commercial ServicesCommercial Services Part of Ernst & Young Global Ltd., Ernst & Young AS is a Norwegian company that provides accounting services. The company is based in Oslo, Norway. The CEO of the company is Christin Erichsen Bøsterud. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
Radiumhospitalets Forskningsstiftelse
![]() Radiumhospitalets Forskningsstiftelse Financial ConglomeratesFinance Radiumhospitalets Forskningsstiftelse invests in companies from Nordic research institutions. It is a pre-seed investor and project developer focused on cancer. It strengthens cancer research at Rikshospitalet University Hospital, including The Norwegian Radium Hospital. It provides Oslo Cancer Cluster with the necessary infrastructure and management team, as well. The company was founded in 1986 and is headquartered in Lysaker, Norway. | Financial Conglomerates | Chief Investment Officer | |
Oslo Cancer Cluster NCE
![]() Oslo Cancer Cluster NCE Miscellaneous Commercial ServicesCommercial Services Oslo Cancer Cluster NCE is an oncology research firm that specializes in developing cancer diagnostics and medicines. The private company is based in Oslo, Norway. | Miscellaneous Commercial Services | Director/Board Member | |
NYKODE THERAPEUTICS | Pharmaceuticals: Major | Chairman | |
CIRCIO HOLDING ASA | Biotechnology | Director/Board Member | |
Pfizer AS
![]() Pfizer AS Pharmaceuticals: MajorHealth Technology Pfizer AS operates as biopharmaceutical company, which engages in the development and manufacture of pharmaceutical products. It develops and produces medicines such as penicillin; vaccines; and medicines for the treatment of cancer, pain, cardiovascular disease, diabetes, mental illness, and rheumatism. The firm also offers drugs against parasites. The company was founded on November 25, 1959 and is headquartered in Oslo, Norway. | Pharmaceuticals: Major | Corporate Officer/Principal | |
AstraZeneca AS | Corporate Officer/Principal | ||
Adaptimmune Ltd.
![]() Adaptimmune Ltd. Medical/Nursing ServicesHealth Services Adaptimmune Ltd. develops T cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases. It utilizes the T cell to target and destroy cancerous and infected cells by using affinity T cell receptor proteins as a means of strengthening patient T cell responses. The company was founded by Bent K. Jakobsen, James Julian Noble and Helena Katrina Tayton-Martin in 2008 and is headquartered in Oxford, the United Kingdom. | Medical/Nursing Services | Founder | |
Norwegian School of Economics & Business Administration | College/University | Graduate Degree | |
BERGENBIO ASA | Pharmaceuticals: Major | Director/Board Member | |
Birk Venture AS
![]() Birk Venture AS Investment ManagersFinance Birk Venture AS (Birk Venture) is an independent Scandinavian venture capital firm which was founded in 2010 by Hans Ivar Robinson. Based in Oslo, Norway, the firm focuses exclusively on the life science industry, utilizing their industry experience and international network to partner with young companies with significant growth prospects. | Investment Managers | Chief Executive Officer | |
Svanhild og Arne Musts fond for medisinsk forskning | Investment Trusts/Mutual Funds | Corporate Officer/Principal | |
SpinChip Diagnostics AS
![]() SpinChip Diagnostics AS Electronic Equipment/InstrumentsElectronic Technology SpinChip Diagnostics AS develops a game changing and proprietary platform for in vitro diagnostics point of care analyses. Its point of care device will satisfy all key user requirements, both with respect to assaying performance and user-friendliness. The firm's platform combines swift analysis and ease of use with wide range of advanced analyses. The company was founded by Stig Morten Borch in February 2012 and is headquartered in Oslo, Norway. | Electronic Equipment/Instruments | Director/Board Member | |
PCI BIOTECH HOLDING ASA | Biotechnology | Chairman | |
Engimmune Therapeutics AG
![]() Engimmune Therapeutics AG Packaged SoftwareTechnology Services Engimmune Therapeutics AG is a developer of off-the-shelf soluble T-cell receptor drugs to treat solid tumors. The company is based in Allschwil, Switzerland. The Swiss company's proprietary platform technologies enable them to engineer stable, multi-specific TCRs that have high affinity for target cancer antigens and trigger a potent and durable anti-cancer T-cell response without causing damage to healthy cells. The company was founded in 2021 as a spin-off of ETH Zurich from technologies developed by Dr. Rodrigo Vazquez-Lombardi and Professor Sai Reddy. Lars Nieba has been the CEO of the company since 2023. | Packaged Software | Chairman | |
ADAPTIMMUNE THERAPEUTICS PLC | Biotechnology | Founder | |
The Institute of Molecular Medicine | Corporate Officer/Principal | ||
IMMUNOCORE HOLDINGS PLC | Biotechnology | Founder | |
Artbio AS
![]() Artbio AS BiotechnologyHealth Technology Part of Artbio, Inc., Artbio AS is a clinical-stage radiopharmaceutical biotechnology business that works to create a new class of alpha radio ligand medicines. The company is based in Oslo, Norway. The Norwegian company was founded in 2018. The CEO is Emanuele Ostuni. | Biotechnology | Director/Board Member |
Statistiques
Internationale
Norvège | 24 |
Royaume-Uni | 6 |
Suisse | 2 |
Etats-Unis | 2 |
Sectorielle
Health Technology | 14 |
Commercial Services | 4 |
Finance | 4 |
Consumer Services | 3 |
Technology Services | 3 |
Opérationnelle
Director/Board Member | 18 |
Chairman | 8 |
Founder | 7 |
Corporate Officer/Principal | 7 |
Chief Tech/Sci/R&D Officer | 3 |
Relations les plus connectées
Insiders | |
---|---|
Anders Tuv | 12 |
Hans Ivar Robinson | 11 |
Bent K. Jakobsen | 8 |
Hans Peter Bøhn | 5 |
Gustav Gaudernack | 1 |
Anders Holm | 1 |
- Bourse
- Insiders
- Namir Hassan
- Connexions Sociétés